[ad_1]
It is the first to prove that the survival of allogeneic iPSCs can be transplanted into an immunologically active non-human primate model without immunosuppression
Transplanting allogeneic cells into primates without immunosuppression represents a critical step in the use of engineered cells to treat diseases in a wide range
Seattle, June 26, 2021 (Global News Agency) – Sana Biotechnology, Inc. (NASDAQ:you), a company focused on creating and providing engineered cells as drugs, today provides data showing that transplanted stem cells survive without immunosuppression in non-human primates (NHPs). The transplanted cells are induced pluripotent stem cells (iPSCs), with Sana’s low-immunity genetic modification, which can evade immunity. At the cell therapy and tissue engineering plenary session at the 2021 virtual annual meeting of the International Society for Stem Cell Research, Sonja Schrepfer, MD and PhD, the head of Sana’s low immunity platform, introduced the data.
Steve Harr, President and CEO of Sana, said: “These findings represent a major breakthrough in cell transplantation, because in non-human primates with healthy immune systems, there has never been It has achieved proof of immune evasion and long-lasting cell survival.” “Since organ, tissue, and cell transplantation first appeared, immune rejection of allogeneic transplantation has been a major challenge hindering the widespread application of these therapies. Our team is now in a variety of The potential of these genetically modified cells has been demonstrated in animal models, and the next step is to apply this technology to a variety of human therapeutic environments. Our first investigational new drug (IND) application will be carried out as early as next year.”
Transplanting cells or tissues from a donor to a different recipient currently requires strong immunosuppression to prevent transplant rejection. The goal of Sana’s low immunity (HIP) platform is to eliminate the need for immunosuppression by hiding immune recognition cells. The platform disrupts major histocompatibility (MHC) class I and MHC class II expression to hide cells from the adaptive immune system, including antibodies and T cell responses. However, these changes make cells vulnerable to innate immune cells, especially natural killer (NK) cells. Sana’s HIP platform also provides overexpression of CD47, a molecule that protects HIP-modified cells from innate cell killing involving NK cells or macrophages. HIP-modified pluripotent stem cells can be used as starting materials for cell-based therapies and differentiate into specialized cell types. Sana’s goal is to use these HIP-modified cells…
The full story on Benzinga.com
[ad_2]
Source link
